Latest News and Press Releases

LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADC Therapeutics S.A., (“ADC" or the "Company") (NYSE: ADCT) investors that the firm has initiated an investigation into...

ICP-B794 demonstrated potent anti-tumor activity in preclinical tumor models and a significantly larger safety window compared to similar drugs.

Promatix Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for ADCs

Presentations highlight therapy-induced senescence as a new opportunity and reinforce STX-1’s potential as a differentiated approach in solid tumors.

At AACR 2026, Callio Therapeutics will present data that highlight the potential of CLIO-8221 as a therapeutic option for HER2-expressing cancers

BioNTech gab heute positive Ergebnisse aus der primären Analyse einer Phase-2-Kohorte mit Trastuzumab Pamirtecan bei HER2+ Gebärmutterkrebs bekannt.

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s...

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.

Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...